REPH
$2.50
Recro Pharma
$.12
5.04%
REPH
Earnings Whisper ®
N/A
4th Quarter December 2020
Consensus:  ($0.18)
Revenue:  $18.50 Mil
Monday
Feb 8
7:00 AM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch
Latest EPS
Monday, November 9, 2020

What do you expect when REPH reports earnings?
Beat
Meet
Miss

Where is REPH's stock price going from here?
Up
Flat
Down
Stock chart of REPH
Analysts
Summary of analysts' recommendations for REPH
Score
Grade
Pivots
Resistance
$2.75
$2.64
$2.57

$2.47

Support
$2.39
$2.29
$2.22
Tweet
Growth
Description
Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania.
Peers
InterCeptRegeneron PharmaceuticalsVertex PharmaceuticalsBioMarin PharmaceuticalBristol-Myers SquibbZoetisMerck & Co.PfizerJohnson & JohnsonEli Lilly